Navigation Links
Repligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders
Date:1/20/2011

WALTHAM, Mass., Jan. 20, 2011 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.  The patent application is based on work conducted at UCI by Dr. Marcelo A. Wood, which demonstrated that one of Repligen's HDAC3 inhibitors improved both the acquisition and persistence of long-term memory in an animal model.  These data were published in the January 12th issue of The Journal of Neuroscience in a manuscript entitled "HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation" (McQuown, S., et al., J. Neurosci. (2011) 31:764 –774).  Under the terms of the license agreement, UCI will receive an upfront payment, development milestones and royalties upon successful commercialization of an HDAC3 inhibitor for certain memory disorders.  Upon issue, the patent will remain in force until 2031 prior to any regulatory extensions.

"These new data indicate that HDAC3 inhibitors should be further evaluated for use in a variety of disorders in which the acquisition or extinction of a long-term memory is a factor," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We intend to continue to investigate the potential of our selective HDAC3 inhibitors in a variety of disease models."

The manuscript published in The Journal of Neuroscience examined the role of HDAC3 inhibitors in long-term memory using a combined genetic and pharmacologic approach.  In the study, a genetic approach was used to delete HDAC3 in the hi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... NAGOYA, Japan , Aug. 19, 2014 ... ASAHI INTECC (Securities Code 7747, Second Section, ... plans to develop a new, differentiated fractional flow reserve ... device intended to improve handling compared to existing FFR ... field in interventional cardiology that exceeds $250 million worldwide ...
(Date:8/18/2014)... Gamida Cell , a world leader ... that it has signed an investment and option agreement with ... " ) . According to the agreement, Novartis ... will receive 15% equity and an option to fully acquire ... of time following achievement of certain milestones connected to the ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new ... Global Operating Room Equipment Market ... About Operating Room Equipment ... a sterile environment in a healthcare facility used ... technically advanced equipment, which ensures patient care and ...
Breaking Medicine Technology:Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Global Operating Room Equipment Market 2014-2018 2Global Operating Room Equipment Market 2014-2018 3Global Operating Room Equipment Market 2014-2018 4Global Operating Room Equipment Market 2014-2018 5Global Operating Room Equipment Market 2014-2018 6
... Cumberland Pharmaceuticals Inc. (Nasdaq: ... an exclusive agreement with China,s Harbin Gloria Pharmaceuticals ... ( acetylcysteine ), its injectable drug used to treat ... is used to treat pain and fever in the ...
... Ore., Feb. 28, 2012 For the first ... psoriasis—a disease of the immune system that appears ... million Americans—and psoriatic arthritis—an inflammatory joint and tendon ... Recognition on items that dermatology experts deem effective ...
Cached Medicine Technology:Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China 2Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China 3Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China 4Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China 5National Psoriasis Foundation Launches "Seal of Recognition" for Psoriasis Products 2National Psoriasis Foundation Launches "Seal of Recognition" for Psoriasis Products 3
(Date:8/19/2014)... The elegant bamboo floorings from BambooIndustry.com are ... in an environmentally conscious way with the company’s floorings. ... have an aluminum oxide finish to help resist wear ... areas. , Recently, the company has released its new ... These fresh items are specially made for global customers. ...
(Date:8/19/2014)... As moms and dads prepare their children ... to the normal routine of dropping their little ones off ... MSc, RD encourages them to use the opportunity to ... , Yarker explains, “Kids have small tummies, short attention ... them junk food handouts, use snack time as another daily ...
(Date:8/19/2014)... 2014 BambooIndustry.com, a well-known bamboo product manufacturer ... deckings recently. The company is excited to reveal the ... special offer for all clients. Now, every customer can get ... will last until August 30. , The company’s deckings ... the world for supreme durability. They are perfect for a ...
(Date:8/19/2014)... Dentistry in Houston, Texas, is pleased to announce it is ... or with old fillings that need replacing, will benefit from ... restore teeth. , From now on any cavities will be ... completely amalgam free. Even though amalgam fillings have been deemed ... and children over the age of six, they do contain ...
(Date:8/19/2014)... Il (PRWEB) August 20, 2014 For ... allopathic medical world that chiropractic adjustments are dangerous and ... and this is why they do not recommend chiropractic ... more educated medical doctors do refer to chiropractors because ... However a statement regarding new research has popped up ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com Announces Up To 30% Discount On Its New Click Strand Woven Bamboo Floorings 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 2Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 3Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 4
... Shannon Malloy, critically injured in a car accident, skull separating ... call her recovery a miracle. ,A car ... her spine, although her skin, spinal cord and other internal ... internal decapitation, and it left her with no control over ...
... treatments. Since it is a very painful process, continuous attempts ... for the patient. ,Now researchers say that LHRH ... stop the production of a female hormone that encourages some ... action, often mimicking the action of a naturally occurring substance. ...
... and performance of other activities but as it turns out, ... ,This is the finding of a team of ... of Alberta. ,As a part study that was ... Canada, the researchers studied 24 patients, two-thirds of whom showed ...
... Moderate drinking may lower the risk of a type of ... ,The researchers at Brigham and Women's Hospital in ... of one alcoholic beverage a day were about 30 percent ... reduced risk they found in people who drank beer, wine ...
... towards making addition of folic acid to flour or bread mandatory ... disabilities. ,After lengthy public consultations the Food Standards ... its recommendations next month after it decides whether folic acid should ... ministers accept the FSA's proposals, it will be the first time ...
... a recent report, says that health specialists were able to ... the 2005 Bali bombings, thanks to improved procedures and services ... at the Royal Darwin Hospital who treated many of the ... health nurses. ,Says Anthony Guscott from Top End ...
Cached Medicine News:Health News:30-year-old Woman Survives 'internal Decapitation' 2Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3Health News:Bali Bombings Helped Improve Trauma Care 2Health News:Bali Bombings Helped Improve Trauma Care 3
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
Medicine Products: